| |
|
PRESS
September 2006
The Diagnostic Center for Disease
"Setting the Standard for Urology Excellence"
The Diagnostic Center for Disease® representing the most advanced prostate cancer detection imaging technology and
interpretation in the world announces the Grand Opening of its World Headquarters in Sarasota, Florida for December 2006.
Specifically, the center will feature a 3.0 Tesla Signa HD-X Magnetic Resonance Imaging Spectroscopy (MRIS) scanner from
General Electric, the world leader in image technology. The signature “Prostascan” image technology will provide a unique
biochemical "finger print" of cancerous tissue (if present) as it evaluates the by-products of metabolism at the prostate
cellular level. Peter Scardino, M.D., Medical Director of the Department of Urology at Memorial Sloan-Kettering has been
quoted as saying, "This is the next greatest advancement in prostate cancer diagnostic testing". According to Hedvig
Hricak, M.D., Chair of the Department of Radiology at Memorial Sloan-Kettering, "the MRIS is a non-invasive diagnostic
technology that gives the patient and the doctor a clear road map for treatment while tailored to the individual patient;
doing what is necessary and nothing more". Candidates for this unique technology include:
- Men with an elevated PSA (greater than 1.0 ng/ml), who want to avoid a
random biopsy while choosing to improve the odds of finding a cancer if present, (realizing; 70-80% of all prostate
biopsies traditionally performed fail to yield a cancer)
- Men who have a PSA value in excess of 1.0 ng/ml, with a family history
of prostate cancer despite a normal digital prostate exam
- Men who understand that Prostate Cancer is over-treated and want to
Avoid a Biopsy
- Men who choose to monitor a low level of prostate cancer and live with
the disease, without the risk of impotency or incontinence
- Men who have experienced the biopsy one or more times and want to
improve the sensitivity of diagnosis for cancer, if present
- Physicians who want to localize prostate cancer so that fewer biopsies
are required, when either a nodule and/or PSA suggests suspicion
- Patients who elect to choose a comprehensive, conservative alternative
to repeat biopsies when they receive the diagnosis of HGPIN or ASAP
- Patients (and physicians) who want to evaluate the true extent of the
disease when a prostate biopsy is positive
To learn more about the MRIS, get a brochure or to schedule an appointment
for your non-invasive diagnostic test, please contact
The Diagnostic Center for Disease ®
1250 Tamiami Trail
Sarasota, Florida 34239
941.957.0007
1-866-674-7872(MRIS USA)
www.mrisprostatecancercenter.com
May 2006
The Prostatitis & Prostate Cancer Center
Sarasota, FL
In April, Dr. Wheeler was trained on HIFU (High Intensity Focused Ultrasound). To research more about this new, exciting
treatment for Prostate Cancer & BPH please visit www.ushifu.com
April 2006
The Prostatitis & Prostate Cancer Center
Sarasota, FL
Dr. Wheeler presents study in the April issue of USTOO demonstrating that Prostate Cancer is over treated.
For more information click
here
March 2006
The Prostatitis & Prostate Cancer Center
Sarasota, FL
Dr. Wheeler to bring MRIS Spectroscopy technology to Sarasota in the latter part of 2006
In the latter part of 2006, Dr. Wheeler expects to bring the next greatest prostate cancer detection technology to
Sarasota, Florida. Specifically, Magnetic Resonance Imaging Spectroscopy (MRIS), applied with an ultrasound type hand-held
probe, will provide a unique "finger print" representation of cancer (if present) as it evaluates the by-products of
metabolism at the prostate cellular level. Please visit
www.mrisprostatecancercenter.com
February 2006
The Prostatitis & Prostate Cancer Center
Sarasota, FL
Dr. Wheeler Presents Prostate Cancer Study to the American Society of Clinical Oncology (Prostate Cancer Symposium) in
San Francisco
Prostate Cancer is arguably the most significant health risk that men face with a new case diagnosed every three minutes.
When prostate cancer is detected, men are offered and accept some form of definitive therapy in the majority of cases with
hopes for a cure. History teaches us that 40-60% of men will have a recurrence of cancer by 7-10 years. Even more
confounding is the inability to predictably define which patients will succeed with a reasonable level of confidence when
the diagnosis is made. Dr. Wheeler’s viable alternative to surgery and/or radiation that preserves quality of life while
allowing men to live with prostate cancer is called Chronic Disease Management (CDM)
November 2004
The following is supportive data to the enclosed abstract and patient performance data on this breaking story.
The Prostatitis & Prostate Cancer Center
Sarasota, Florida
With a new case of prostate cancer diagnosed every 3 minutes, there is concern that without novel, beneficial, less costly
methodologies to treat the cancer the health care system will be at risk. The late William Fair, M.D. (former Chairman of
Surgery and Urology at Memorial Sloan-Kettering), who championed the cause of Integrative Medicine, stated in the year
2000, "Based on everything we know about prostate cancer, I am not certain that it should not be treated as a chronic
disease”. Dr. Fair's frustration was noted in the inability to predictably cure prostate cancer when it was detected.
Challenging the concept of treatment for cure, the late Willet Whitmore, M.D. (Memorial Sloan-Kettering) asked the
rhetorical question in a now famous quote, “Is it possible to cure prostate cancer when it is necessary and is it
necessary to cure prostate cancer when it is possible"?
Concentrating on the later part of the rhetorical question, I have evaluated men with known prostate cancer with a
modified Mediterranean diet and a patented prostate nutritional formula called Peenuts ®,. I believe I have developed a
viable treatment modality for men with moderately well differentiated prostate cancer. The results of this prospective
study are exceptional as the prostate cancer process has just reversed itself or stopped growing. Importantly, all men
entered in the study did well. The only qualification for study entry was that a man needed a biopsy proven moderately
well differentiated prostate cancer consistent with a Gleason score of 5 or 6 (range: 2-10).
The financial impact of transitioning men who choose to live with their cancer will be in the billions of dollars saved,
as minimally 50-60% of all prostate cancers fit this category. Additionally, men will be spared a quality of life altering
procedure including Radical Prostatectomy or Radiation. While patients in this study protocol still qualify for these
“definitive procedures” in the event they change their minds, there is no indication that a more aggressive treatment is
required. As the study results point out, 90% of the patients suppressed their cancer while 10% remained stable at an
average disease surveillance of 30 months. Minimally the findings associated with this study give patients an additional
option, with renewed hope for a better quality of life, when prostate cancer is diagnosed.
Please feel free to contact me with questions or comments at 1-941-957-0007.
Sincerely,
Ronald E. Wheeler, M.D.
|
